Fröhlich, Albrecht
Olde Heuvel, Florian
Rehman, Rida
Krishnamurthy, Sruthi Sankari
Li, Shun
Li, Zhenghui
Bayer, David
Conquest, Alison
Hagenston, Anna M.
Ludolph, Albert
Huber-Lang, Markus
Boeckers, Tobias
Knöll, Bernd
Morganti-Kossmann, Maria Cristina
Bading, Hilmar
Roselli, Francesco
Funding for this research was provided by:
China Sponsorship Council (201908320357)
Deutsche Forschungsgemeinschaft (251293561)
Bundesministerium für Bildung und Forschung (FKZ 01EW1705A)
Universität Ulm
Article History
Received: 3 April 2022
Accepted: 30 October 2022
First Online: 19 November 2022
Declarations
:
: All animal experiments were approved by the Tierforschungszentrum Ulm and by the Regierungspraesidium Tubingen with licence no. 1420. The collection of CSF samples from human TBI patients was authorized by The Alfred Hospital Ethical Committee (Melbourne) licence no. 194–05 to Cristina Morganti-Kossmann and by the Ulm University Ethical Committee licence no. 12/19-22050.
: Not applicable.
: HB is the founder and shareholder of Fundamental Pharma GmbH and he is the inventor of a patent related to the present study (USA: US9415090; Canada: CA283483; European Office: EP2714063). The other authors declare no conflict of interest.